Legal Opinion
Amerigen Pharmaceuticals v. Ucb Pharma Gmbh
Court of Appeals for the Federal Circuit
Decided January 11, 2019No. 2017-2596PublishedCited by 16 opinions
1Opinion of the Court
Lourie, Circuit Judge.
*1078 Amerigen Pharmaceuticals Limited ("Amerigen") appeals from the decision of the United States Patent and Trademark Office Patent Trial and Appeal Board (the "Board") in an inter partes review ("IPR") holding that claims 1-5 and 21-24 of U.S. Patent 6,858,650 (the " '650 patent") are not unpatentable as obvious. Mylan Pharm. Inc. v. UCB Pharma GmbH , No. 2016-00510, 2017 WL 3085867 (P.T.A.B. July 19, 2017) (" Decision "). We conclude that the Board did not err in its conclusions and affirm.
I. BACKGROUND
A
UCB Pharma GmbH ("UCB") owns the '650 patent, which covers certain…
2Cases cited20 opinions
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- Consolidated Edison Co. v. National Labor Relations BoardSupreme Court of the United States · 1938
- Warth v. SeldinSupreme Court of the United States · 1975
- Spokeo, Inc. v. RobinsSupreme Court of the United States · 2016
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
15 more not listed; retrieve them via the Exa API.
3Cited by16 opinions
- Bradium Techs. LLC v. Andrei IANCUCourt of Appeals for the Federal Circuit · 2019
- Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLCCourt of Appeals for the Federal Circuit · 2019
- Adapt Pharma Operations v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2022
- Adidas Ag v. Nike, Inc.Court of Appeals for the Federal Circuit · 2020
- General Electric Company v. Raytheon Technologies Corp.Court of Appeals for the Federal Circuit · 2020
11 more not listed; retrieve them via the Exa API.